1. Clinical Overview
Pegylated Interferon Alpha 2B is a long-acting, covalent conjugate of recombinant human interferon alpha-2b with a single, linear 12 kDa polyethylene glycol (PEG) chain. This pegylation significantly prolongs its half-life, reduces immunogenicity, and allows for once-weekly subcutaneous administration. It is a potent immunomodulator and antiviral agent, primarily used in the management of chronic hepatitis B and C infections in the Indian context. It exerts its effects by binding to specific cell surface receptors, activating the JAK-STAT signaling pathway, leading to the expression of interferon-stimulated genes (ISGs) that inhibit viral replication and modulate immune responses.
| Onset | Duration | Bioavailability |
|---|---|---|
| Antiviral and immunomodulatory effects begin within hours of administration, but clinical and virological responses (e.g., reduction in viral load) are typically observed over weeks to months of therapy. | Pharmacodynamic effects persist throughout the weekly dosing interval due to sustained serum levels. The biological effects on immune cells can last beyond the detectable serum concentration. | Approximately 80-90% following subcutaneous injection. |
2. Mechanism of Action
Peginterferon alfa-2b binds to specific, high-affinity cell-surface receptors (IFNAR1 and IFNAR2) present on most human cells. This binding activates the intracellular JAK-STAT (Janus kinase-signal transducer and activator of transcription) signaling pathway. Activation leads to the transcription and translation of over 300 Interferon-Stimulated Genes (ISGs). The proteins produced have multiple effects: 1) Direct antiviral activity via induction of enzymes like 2',5'-oligoadenylate synthetase (2-5 OAS) and protein kinase R (PKR) which inhibit viral RNA translation and degrade viral RNA. 2) Immunomodulation by enhancing antigen presentation (upregulation of MHC class I), activating natural killer (NK) cells and cytotoxic T-lymphocytes, and modulating cytokine production.
3. Indications & Uses
- Chronic Hepatitis C (Genotype 1-6) in combination with Ribavirin and/or Direct-Acting Antivirals (DAAs) as per guidelines
- Chronic Hepatitis B (HBeAg positive or negative) with compensated liver disease and evidence of viral replication
4. Dosage & Administration
Adult Dosage: Hepatitis C: 1.5 mcg/kg body weight subcutaneously once weekly. Often used in a weight-based dosing strategy (e.g., 50mcg for patients <40kg, 80mcg for 40-50kg, etc.). The 50mcg vial is part of this weight-based regimen. Hepatitis B: 1.0 mcg/kg subcutaneously once weekly OR 50mcg once weekly fixed dose for patients weighing <40kg. Duration: 24-48 weeks for HCV, 48 weeks for HBV, as per protocol.
Administration: For subcutaneous use only. Provided as a lyophilized powder in a single-use vial. Reconstitute strictly aseptically with 0.7 mL of supplied Sterile Water for Injection. Gently swirl, do not shake. The resulting solution concentration is approximately 70 mcg/mL. Draw the appropriate volume (e.g., ~0.71 mL for a 50mcg dose) into a syringe. Inject SC into the thigh or abdomen, rotating injection sites. Use immediately after reconstitution. Discard any unused portion.
5. Side Effects
Common side effects may include:
- Influenza-like symptoms (fever, chills, headache, myalgia, arthralgia - often managed with pre-dose paracetamol)
- Fatigue, asthenia
- Injection site reactions (erythema, pain, swelling)
- Anorexia, nausea
- Alopecia (reversible)
- Mild psychiatric symptoms (irritability, insomnia)
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Ribavirin | Additive antiviral efficacy against HCV, but also additive risk of hemolytic anemia. Mandatory combination in many HCV regimens. | Major |
| Telbivudine | Increased risk of severe peripheral neuropathy. Concomitant use is contraindicated. | Contraindicated |
| Zidovudine (AZT) | Increased risk of severe neutropenia and anemia. Avoid combination or monitor blood counts intensively. | Major |
| Theophylline | Peginterferon may reduce the clearance of theophylline, increasing its serum levels and risk of toxicity. Monitor theophylline levels. | Moderate |
| Methadone | May increase methadone plasma levels, potentially leading to increased opioid effects. Monitor for sedation and respiratory depression. | Moderate |
| Warfarin | May alter INR; increased monitoring of INR is required. | Moderate |
| Live Vaccines | Theoretical risk of enhanced vaccine-related infections due to immunomodulation. Avoid. | Major |
7. Patient Counselling
- DO administer the injection on the same day each week, as prescribed.
- DO rotate injection sites (thigh, abdomen) to prevent skin reactions.
- DO pre-medicate with paracetamol to manage flu-like symptoms.
- DO maintain adequate fluid intake.
- DO keep all scheduled follow-up appointments for blood tests and clinical evaluation.
- DO use effective contraception (both partners) if taking with Ribavirin.
- DONT skip doses without consulting your doctor.
- DONT shake the reconstituted vial; swirl gently.
- DONT reuse needles or syringes.
- DONT drink alcohol during treatment.
8. Toxicology & Storage
Overdose: Exacerbation of common side effects: severe fatigue, high fever, chills, profound myelosuppression (pancytopenia), severe nausea/vomiting, hypotension, tachycardia, liver enzyme elevations, and severe neuropsychiatric events (coma, seizures).
Storage: Store unopened vials in a refrigerator at 2°C to 8°C. Do not freeze. Protect from light. Keep in the outer carton. After reconstitution, the solution should be used immediately. If not used immediately, it may be stored refrigerated (2°C-8°C) for up to 24 hours. Do not shake. Discard any unused solution after single use.